[1] Schipper RG, et al. Antitumor activity of the polyamine analog N(1), N(11)-diethylnorspermine against human prostate carcinoma cells. Prostate. 2000 Sep 1;44(4):313-21. DOI:
10.1002/1097-0045(20000901)44:43.0.co;2-d[2] Holst CM, et al. Molecular mechanisms underlying N1, N11-diethylnorspermine-induced apoptosis in a human breast cancer cell line. Anticancer Drugs. 2008 Oct;19(9):871-83. DOI:
10.1097/CAD.0b013e32830f902b[3] Jiang R, et al. Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. Int J Oncol. 2007 Aug;31(2):431-40. PMID:17611701
[4] Jiang R, et al. Activation of polyamine catabolism by N1, N11-diethylnorspermine alters the cellular localization of mTOR and downregulates mTOR protein level in glioblastoma cells. Cancer Biol Ther. 2007 Oct;6(10):1644-8. DOI:
10.4161/cbt.6.10.4800[5] Bernacki RJ, et al. Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. Clin Cancer Res. 1995 Aug;1(8):847-57. PMID:9816054
[6] Kanter PM, et al. Preclinical toxicologic evaluation of DENSPM (N1,N11-diethylnorspermine) in rats and dogs. Anticancer Drugs. 1994 Aug;5(4):448-56. DOI:
10.1097/00001813-199408000-00010